Send to

Choose Destination
Exp Oncol. 2010 Jul;32(2):104-6.

Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model.

Author information

Department of Diagnostic Radiology, N.N. Alexandrov National Cancer Center of Belarus, BY 223040 Lesnoj 2, Minsk, Belarus.



To show usefulness of diffusion-weighted magnetic resonance imaging (MRI) for non-invasive assessment of experimental tumor after antiangiogenic treatment.


M1 sarcoma was implanted to the peritoneal cavity of the rat and allowed to grow to a palpable tumor size. Animal was treated with a single injection of endothelial growth factor antibody Bevacizumab (Avastin). Serial MRI scanning including diffusion-weighted sequence was performed before and up to 100 h after treatment. Animal was sacrificed thereafter and MRI data were correlated with morphology.


Apparent diffusion coefficient (ADC) maps derived tumor necrotic area correlated well with histology-derived tumor necrotic area. ADC threshold of 1.39 x 10(-3) mm(2)/s appeared to be optimal for tumor necrosis quantification in this tumor model and allowed to follow temporal changes of tumor internal structure after treatment.


Diffusion-weighted MRI permits non-invasive tissue characterization without the need for exogenous contrast agents and, therefore, may be used to individualise therapy and to monitor tumor response.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center